Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Dimou on Progress Made in ALK+ Lung Cancer Treatment

April 15th 2020

Anastasios (Tassos) Dimou, MD, discusses the progress made in the treatment of patients with ALK-positive lung cancer.

Liquid Biopsy Detects Alterations That Confer Resistance to Alpelisib in HR+ Breast Cancer

April 15th 2020

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors in patients with hormone receptor–positive metastatic breast cancer.

Other Trials of Interest in Renal Cancers

April 14th 2020

Promising Second-Line Therapies for mRCC

April 14th 2020

Progress in First-Line mRCC

April 14th 2020

Combination Therapies to Overcome Resistance in mRCC

April 14th 2020

VEGF TKI Therapy After I/O in mRCC

April 14th 2020

Second-Line Therapy After I/O in mRCC

April 14th 2020

mRCC: Resistance to VEGF and I/O

April 14th 2020

IMDC Criteria and Targeted Therapy in mRCC

April 14th 2020

VEGF-TKI Therapy in First-Line mRCC

April 14th 2020

SBRT in Combination With Ipilimumab/Nivolumab in mRCC

April 14th 2020

Ipilimumab/Nivolumab for Favorable-Risk mRCC

April 14th 2020

iRECIST Criteria and First-Line Treatment of mRCC

April 14th 2020

Ipilimumab/Nivolumab in First-Line mRCC

April 14th 2020

Cytoreductive Nephrectomy After I/O in mRCC

April 14th 2020

Cytoreductive Nephrectomy in mRCC: Current Data

April 14th 2020

Role of Cytoreductive Nephrectomy in mRCC

April 14th 2020

Amplicon-Based Liquid Biopsy Detects ALK/ROS1 Fusion and Resistance Mutations in NSCLC

April 13th 2020

Amplicon-based liquid biopsy can detect ALK/ROS1 fusions in TKI-naïve patients with non–small cell lung cancer and allows for the identification of resistance mutations in those treated with TKIs.

The Future of Lung Cancer Management

April 13th 2020